{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:49:33Z","timestamp":1744174173279},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T00:00:00Z","timestamp":1316995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1742-4690-8-75","type":"journal-article","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T06:41:22Z","timestamp":1317105682000},"source":"Crossref","is-referenced-by-count":20,"title":["Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes"],"prefix":"10.1186","volume":"8","author":[{"given":"Wibke","family":"Bayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Lietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teona","family":"Ontikatze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Johrden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Tenbusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Groitl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra M","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"\u00dcberla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,26]]},"reference":[{"key":"2484_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","volume":"23","author":"AN Theofilopoulos","year":"2005","unstructured":"Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I interferons (alpha\/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005, 23: 307-336. 10.1146\/annurev.immunol.23.021704.115843.","journal-title":"Annu Rev Immunol"},{"key":"2484_CR2","doi-asserted-by":"publisher","first-page":"8219","DOI":"10.1128\/JVI.78.15.8219-8228.2004","volume":"78","author":"V van Pesch","year":"2004","unstructured":"van Pesch V, Lanaya H, Renauld JC, Michiels T: Characterization of the murine alpha interferon gene family. J Virol. 2004, 78: 8219-8228. 10.1128\/JVI.78.15.8219-8228.2004.","journal-title":"J Virol"},{"key":"2484_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1089\/107999099314009","volume":"19","author":"L Hibbert","year":"1999","unstructured":"Hibbert L, Foster GR: Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J Interferon Cytokine Res. 1999, 19: 309-318. 10.1089\/107999099314009.","journal-title":"J Interferon Cytokine Res"},{"key":"2484_CR4","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.4049\/jimmunol.160.6.2932","volume":"160","author":"WS Yeow","year":"1998","unstructured":"Yeow WS, Lawson CM, Beilharz MW: Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J Immunol. 1998, 160: 2932-2939.","journal-title":"J Immunol"},{"key":"2484_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1251\/bpo45","volume":"5","author":"EJ Bartlett","year":"2003","unstructured":"Bartlett EJ, Cull VS, Mowe EN, Mansfield JP, James CM: Optimization of naked DNA delivery for interferon subtype immunotherapy in cytomegalovirus infection. Biol Proced Online. 2003, 5: 43-52. 10.1251\/bpo45.","journal-title":"Biol Proced Online"},{"key":"2484_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1046\/j.1365-2567.2002.01423.x","volume":"106","author":"VS Cull","year":"2002","unstructured":"Cull VS, Bartlett EJ, James CM: Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis. Immunology. 2002, 106: 428-437. 10.1046\/j.1365-2567.2002.01423.x.","journal-title":"Immunology"},{"key":"2484_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1251\/bpo118","volume":"8","author":"BA Austin","year":"2006","unstructured":"Austin BA, James CM, Harle P, Carr DJ: Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol Proced Online. 2006, 8: 55-62. 10.1251\/bpo118.","journal-title":"Biol Proced Online"},{"key":"2484_CR8","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.vaccine.2006.10.038","volume":"25","author":"CM James","year":"2007","unstructured":"James CM, Abdad MY, Mansfield JP, Jacobsen HK, Vind AR, Stumbles PA, Bartlett EJ: Differential activities of alpha\/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine. 2007, 25: 1856-1867. 10.1016\/j.vaccine.2006.10.038.","journal-title":"Vaccine"},{"key":"2484_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/eji.200838311","volume":"39","author":"N Gerlach","year":"2009","unstructured":"Gerlach N, Gibbert K, Alter C, Nair S, Zelinskyy G, James CM, Dittmer U: Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol. 2009, 39: 136-146. 10.1002\/eji.200838311.","journal-title":"Eur J Immunol"},{"key":"2484_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009, 49: 1335-1374. 10.1002\/hep.22759.","journal-title":"Hepatology"},{"key":"2484_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1055\/s-0030-1267537","volume":"30","author":"J Wiegand","year":"2010","unstructured":"Wiegand J, van BF, Berg T: Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis. 2010, 30: 361-377. 10.1055\/s-0030-1267537.","journal-title":"Semin Liver Dis"},{"key":"2484_CR12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1126\/science.299.5611.1290","volume":"299","author":"J Cohen","year":"2003","unstructured":"Cohen J: Public health. AIDS vaccine trial produces disappointment and confusion. Science. 2003, 299: 1290-1291. 10.1126\/science.299.5611.1290.","journal-title":"Science"},{"key":"2484_CR13","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1086\/508748","volume":"194","author":"P Pitisuttithum","year":"2006","unstructured":"Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van GF, Hu D, Tappero JW, Choopanya K: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006, 194: 1661-1671. 10.1086\/508748.","journal-title":"J Infect Dis"},{"key":"2484_CR14","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361","author":"S Rerks-Ngarm","year":"2009","unstructured":"Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009, 361: 2209-2220. 10.1056\/NEJMoa0908492.","journal-title":"N Engl J Med"},{"key":"2484_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/5550","volume":"5","author":"U Dittmer","year":"1999","unstructured":"Dittmer U, Brooks DM, Hasenkrug KJ: Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat Med. 1999, 5: 189-193. 10.1038\/5550.","journal-title":"Nat Med"},{"key":"2484_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jinf.2010.03.005","volume":"60","author":"C Sun","year":"2010","unstructured":"Sun C, Zhang L, Zhang M, Liu Y, Zhong M, Ma X, Chen L: Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys. J Infect. 2010, 60: 371-381. 10.1016\/j.jinf.2010.03.005.","journal-title":"J Infect"},{"key":"2484_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1084\/jem.105.4.307","volume":"105","author":"C Friend","year":"1957","unstructured":"Friend C: Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med. 1957, 105: 307-318. 10.1084\/jem.105.4.307.","journal-title":"J Exp Med"},{"key":"2484_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.vaccine.2007.11.050","volume":"26","author":"W Bayer","year":"2008","unstructured":"Bayer W, Schimmer S, Hoffmann D, Dittmer U, Wildner O: Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies. Vaccine. 2008, 26: 716-726. 10.1016\/j.vaccine.2007.11.050.","journal-title":"Vaccine"},{"key":"2484_CR19","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1128\/JVI.01840-09","volume":"84","author":"W Bayer","year":"2010","unstructured":"Bayer W, Tenbusch M, Lietz R, Johrden L, Schimmer S, Uberla K, Dittmer U, Wildner O: Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J Virol. 2010, 84: 1967-1976. 10.1128\/JVI.01840-09.","journal-title":"J Virol"},{"key":"2484_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jim.2005.08.005","volume":"306","author":"M Bollati-Fogolin","year":"2005","unstructured":"Bollati-Fogolin M, Muller W: Virus free, cell-based assay for the quantification of murine type I interferons. J Immunol Methods. 2005, 306: 169-175. 10.1016\/j.jim.2005.08.005.","journal-title":"J Immunol Methods"},{"key":"2484_CR21","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1128\/JVI.70.11.7773-7782.1996","volume":"70","author":"W Chen","year":"1996","unstructured":"Chen W, Qin H, Chesebro B, Cheever MA: Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol. 1996, 70: 7773-7782.","journal-title":"J Virol"},{"key":"2484_CR22","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1128\/JVI.67.8.4533-4542.1993","volume":"67","author":"M Iwashiro","year":"1993","unstructured":"Iwashiro M, Kondo T, Shimizu T, Yamagishi H, Takahashi K, Matsubayashi Y, Masuda T, Otaka A, Fujii N, Ishimoto A, et al: Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol. 1993, 67: 4533-4542.","journal-title":"J Virol"},{"key":"2484_CR23","doi-asserted-by":"publisher","first-page":"12260","DOI":"10.1073\/pnas.0404769101","volume":"101","author":"RJ Messer","year":"2004","unstructured":"Messer RJ, Dittmer U, Peterson KE, Hasenkrug KJ: Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci USA. 2004, 101: 12260-12265. 10.1073\/pnas.0404769101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2484_CR24","doi-asserted-by":"publisher","first-page":"8578","DOI":"10.1073\/pnas.93.16.8578","volume":"93","author":"B Doe","year":"1996","unstructured":"Doe B, Selby M, Barnett S, Baenziger J, Walker CM: Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA. 1996, 93: 8578-8583. 10.1073\/pnas.93.16.8578.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2484_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1084\/jem.20052005","volume":"203","author":"C Trumpfheller","year":"2006","unstructured":"Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, Soares H, Huang Y, Schlesinger SJ, Park CG, Nussenzweig MC, et al: Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med. 2006, 203: 607-617. 10.1084\/jem.20052005.","journal-title":"J Exp Med"},{"key":"2484_CR26","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.4049\/jimmunol.176.8.4682","volume":"176","author":"A Le Bon","year":"2006","unstructured":"Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, Kalinke U, Tough DF: Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol. 2006, 176: 4682-4689.","journal-title":"J Immunol"},{"key":"2484_CR27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/sj.gt.3301809","volume":"9","author":"VS Cull","year":"2002","unstructured":"Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM: Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther. 2002, 9: 1369-1378. 10.1038\/sj.gt.3301809.","journal-title":"Gene Ther"},{"key":"2484_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jmv.20264","volume":"75","author":"S Gehring","year":"2005","unstructured":"Gehring S, Gregory SH, Kuzushita N, Wands JR: Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein. J Med Virol. 2005, 75: 249-257. 10.1002\/jmv.20264.","journal-title":"J Med Virol"},{"key":"2484_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00109-003-0452-9","volume":"81","author":"M Kwissa","year":"2003","unstructured":"Kwissa M, Kroger A, Hauser H, Reimann J, Schirmbeck R: Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination. J Mol Med. 2003, 81: 91-101.","journal-title":"J Mol Med"},{"key":"2484_CR30","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1016\/j.vaccine.2006.04.059","volume":"24","author":"WW Leitner","year":"2006","unstructured":"Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP: Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine. 2006, 24: 5110-5118. 10.1016\/j.vaccine.2006.04.059.","journal-title":"Vaccine"},{"key":"2484_CR31","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.4049\/jimmunol.180.11.7158","volume":"180","author":"SL Day","year":"2008","unstructured":"Day SL, Ramshaw IA, Ramsay AJ, Ranasinghe C: Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy. J Immunol. 2008, 180: 7158-7166.","journal-title":"J Immunol"},{"key":"2484_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.virol.2008.09.019","volume":"382","author":"EJ Faul","year":"2008","unstructured":"Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ: Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology. 2008, 382: 226-238. 10.1016\/j.virol.2008.09.019.","journal-title":"Virology"},{"key":"2484_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2010.11.007","volume":"89","author":"Y Kumaki","year":"2011","unstructured":"Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, Smith AJ, Bailey KW, Vest ZG, Madsen JR, Li JK, et al: Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB\/c mouse model. Antiviral Res. 2011, 89: 75-82. 10.1016\/j.antiviral.2010.11.007.","journal-title":"Antiviral Res"},{"key":"2484_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1099\/vir.0.015834-0","volume":"91","author":"SR Nair","year":"2010","unstructured":"Nair SR, Zelinskyy G, Schimmer S, Gerlach N, Kassiotis G, Dittmer U: Mechanisms of control of acute Friend virus infection by CD4+ T helper cells and their functional impairment by regulatory T cells. J Gen Virol. 2010, 91: 440-451. 10.1099\/vir.0.015834-0.","journal-title":"J Gen Virol"},{"key":"2484_CR35","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1128\/JVI.75.7.3152-3163.2001","volume":"75","author":"N Iwanami","year":"2001","unstructured":"Iwanami N, Niwa A, Yasutomi Y, Tabata N, Miyazawa M: Role of natural killer cells in resistance against friend retrovirus-induced leukemia. J Virol. 2001, 75: 3152-3163. 10.1128\/JVI.75.7.3152-3163.2001.","journal-title":"J Virol"},{"key":"2484_CR36","doi-asserted-by":"crossref","first-page":"748","DOI":"10.4049\/jimmunol.155.2.748","volume":"155","author":"M Miyazawa","year":"1995","unstructured":"Miyazawa M, Fujisawa R, Ishihara C, Takei YA, Shimizu T, Uenishi H, Yamagishi H, Kuribayashi K: Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J Immunol. 1995, 155: 748-758.","journal-title":"J Immunol"},{"key":"2484_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/viro.2000.0356","volume":"272","author":"U Dittmer","year":"2000","unstructured":"Dittmer U, Hasenkrug KJ: Different immunological requirements for protection against acute versus persistent Friend retrovirus infections. Virology. 2000, 272: 177-182. 10.1006\/viro.2000.0356.","journal-title":"Virology"},{"key":"2484_CR38","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/14.4.411","volume":"14","author":"D Braun","year":"2002","unstructured":"Braun D, Caramalho I, Demengeot J: IFN-alpha\/beta enhances BCR-dependent B cell responses. Int Immunol. 2002, 14: 411-419. 10.1093\/intimm\/14.4.411.","journal-title":"Int Immunol"},{"key":"2484_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","volume":"14","author":"A Le Bon","year":"2001","unstructured":"Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF: Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001, 14: 461-470. 10.1016\/S1074-7613(01)00126-1.","journal-title":"Immunity"},{"key":"2484_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/JVI.75.1.52-60.2001","volume":"75","author":"M Iwashiro","year":"2001","unstructured":"Iwashiro M, Peterson K, Messer RJ, Stromnes IM, Hasenkrug KJ: CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection. J Virol. 2001, 75: 52-60. 10.1128\/JVI.75.1.52-60.2001.","journal-title":"J Virol"},{"key":"2484_CR41","doi-asserted-by":"publisher","first-page":"11211","DOI":"10.1128\/JVI.01225-09","volume":"83","author":"R Pike","year":"2009","unstructured":"Pike R, Filby A, Ploquin MJ, Eksmond U, Marques R, Antunes I, Hasenkrug K, Kassiotis G: Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection. J Virol. 2009, 83: 11211-11222. 10.1128\/JVI.01225-09.","journal-title":"J Virol"},{"key":"2484_CR42","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.4049\/jimmunol.0900526","volume":"184","author":"L Pace","year":"2010","unstructured":"Pace L, Vitale S, Dettori B, Palombi C, La SV, Belardelli F, Proietti E, Doria G: APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol. 2010, 184: 5969-5979. 10.4049\/jimmunol.0900526.","journal-title":"J Immunol"},{"key":"2484_CR43","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.4049\/jimmunol.176.6.3315","volume":"176","author":"C Havenar-Daughton","year":"2006","unstructured":"Havenar-Daughton C, Kolumam GA, Murali-Krishna K: Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J Immunol. 2006, 176: 3315-3319.","journal-title":"J Immunol"},{"key":"2484_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1084\/jem.189.3.521","volume":"189","author":"P Marrack","year":"1999","unstructured":"Marrack P, Kappler J, Mitchell T: Type I interferons keep activated T cells alive. J Exp Med. 1999, 189: 521-530. 10.1084\/jem.189.3.521.","journal-title":"J Exp Med"},{"key":"2484_CR45","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1128\/JVI.66.7.4497-4507.1992","volume":"66","author":"M Miyazawa","year":"1992","unstructured":"Miyazawa M, Nishio J, Chesebro B: Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol. 1992, 66: 4497-4507.","journal-title":"J Virol"},{"key":"2484_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ymthe.2006.02.015","volume":"14","author":"E Huarte","year":"2006","unstructured":"Huarte E, Larrea E, Hernandez-Alcoceba R, Alfaro C, Murillo O, Arina A, Tirapu I, Azpilicueta A, Hervas-Stubbs S, Bortolanza S, et al: Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther. 2006, 14: 129-138. 10.1016\/j.ymthe.2006.02.015.","journal-title":"Mol Ther"},{"key":"2484_CR47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2217\/imt.11.74","volume":"3","author":"K Gibbert","year":"2011","unstructured":"Gibbert K, Dittmer U: Distinct antiviral activities of IFN-alpha subtypes. Immunotherapy. 2011, 3: 813-816. 10.2217\/imt.11.74.","journal-title":"Immunotherapy"},{"key":"2484_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmb.2006.11.053","volume":"366","author":"E Jaks","year":"2007","unstructured":"Jaks E, Gavutis M, Uze G, Martal J, Piehler J: Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol. 2007, 366: 525-539. 10.1016\/j.jmb.2006.11.053.","journal-title":"J Mol Biol"},{"key":"2484_CR49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/nar\/13.3.791","volume":"13","author":"EC Zwarthoff","year":"1985","unstructured":"Zwarthoff EC, Mooren AT, Trapman J: Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res. 1985, 13: 791-804. 10.1093\/nar\/13.3.791.","journal-title":"Nucleic Acids Res"},{"key":"2484_CR50","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/JVI.52.2.695-698.1984","volume":"52","author":"MR Lander","year":"1984","unstructured":"Lander MR, Chattopadhyay SK: A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J Virol. 1984, 52: 695-698.","journal-title":"J Virol"},{"key":"2484_CR51","doi-asserted-by":"publisher","first-page":"6950","DOI":"10.1093\/nar\/19.24.6950","volume":"19","author":"S Perryman","year":"1991","unstructured":"Perryman S, Nishio J, Chesebro B: Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res. 1991, 19: 6950-10.1093\/nar\/19.24.6950.","journal-title":"Nucleic Acids Res"},{"key":"2484_CR52","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1089\/104303400750038507","volume":"11","author":"R Wagner","year":"2000","unstructured":"Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, Foley P, Uberla K: Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther. 2000, 11: 2403-2413. 10.1089\/104303400750038507.","journal-title":"Hum Gene Ther"},{"key":"2484_CR53","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","volume":"72","author":"I Dmitriev","year":"1998","unstructured":"Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998, 72: 9706-9713.","journal-title":"J Virol"},{"key":"2484_CR54","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/sj.jid.5701131","volume":"128","author":"D Hoffmann","year":"2008","unstructured":"Hoffmann D, Bayer W, Heim A, Potthoff A, Nettelbeck DM, Wildner O: Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. J Invest Dermatol. 2008, 128: 988-998. 10.1038\/sj.jid.5701131.","journal-title":"J Invest Dermatol"},{"key":"2484_CR55","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1128\/JVI.70.11.7498-7509.1996","volume":"70","author":"N Mittereder","year":"1996","unstructured":"Mittereder N, March KL, Trapnell BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996, 70: 7498-7509.","journal-title":"J Virol"},{"key":"2484_CR56","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/312548a0","volume":"312","author":"SP Cobbold","year":"1984","unstructured":"Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H: Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984, 312: 548-551. 10.1038\/312548a0.","journal-title":"Nature"},{"key":"2484_CR57","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.140.6.1457","volume":"140","author":"B Chesebro","year":"1974","unstructured":"Chesebro B, Wehrly K, Stimpfling J: Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med. 1974, 140: 1457-1467. 10.1084\/jem.140.6.1457.","journal-title":"J Exp Med"},{"key":"2484_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1006\/viro.1998.9264","volume":"248","author":"KJ Hasenkrug","year":"1998","unstructured":"Hasenkrug KJ, Brooks DM, Robertson MN, Srinivas RV, Chesebro B: Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology. 1998, 248: 66-73. 10.1006\/viro.1998.9264.","journal-title":"Virology"},{"key":"2484_CR59","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/0042-6822(85)90187-4","volume":"141","author":"M Sitbon","year":"1985","unstructured":"Sitbon M, Nishio J, Wehrly K, Lodmell D, Chesebro B: Use of a focal immunofluorescence assay on live cells for quantitation of retroviruses: distinction of host range classes in virus mixtures and biological cloning of dual-tropic murine leukemia viruses. Virology. 1985, 141: 110-118. 10.1016\/0042-6822(85)90187-4.","journal-title":"Virology"},{"key":"2484_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0166-0934(91)90105-9","volume":"34","author":"MN Robertson","year":"1991","unstructured":"Robertson MN, Miyazawa M, Mori S, Caughey B, Evans LH, Hayes SF, Chesebro B: Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods. 1991, 34: 255-271. 10.1016\/0166-0934(91)90105-9.","journal-title":"J Virol Methods"},{"key":"2484_CR61","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1046\/j.1365-3083.1998.00323.x","volume":"47","author":"A Fomsgaard","year":"1998","unstructured":"Fomsgaard A, Nielsen HV, Bryder K, Nielsen C, Machuca R, Bruun L, Hansen J, Buus S: Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen. Scand J Immunol. 1998, 47: 289-295. 10.1046\/j.1365-3083.1998.00323.x.","journal-title":"Scand J Immunol"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-4690-8-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1742-4690-8-75\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1742-4690-8-75.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T01:58:23Z","timestamp":1686362303000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/1742-4690-8-75"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,26]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2484"],"URL":"https:\/\/doi.org\/10.1186\/1742-4690-8-75","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,26]]},"article-number":"75"}}